A carregar...
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease
BACKGROUND: Data from trials of vedolizumab for inflammatory bowel disease and from real-world studies suggest an exposure-response relationship, such that vedolizumab trough levels may predict clinical and endoscopic outcomes. OBJECTIVE: The purpose of this study was to evaluate in a prospective ob...
Na minha lista:
| Publicado no: | United European Gastroenterol J |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6826518/ https://ncbi.nlm.nih.gov/pubmed/31700632 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2050640619873784 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|